WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition
(1995; 152 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentPreface
Open this folder and view contentsProtozoa
Close this folderHelminths
Open this folder and view contentsCestode (tapeworm) infection
Close this folderIntestinal nematode infection
View the documentAlbendazole
View the documentLevamisole
View the documentMebendazole
View the documentPiperazine
View the documentPyrantel
View the documentTissue nematode infections
Open this folder and view contentsLoiasis
Open this folder and view contentsLymphatic filariasis
Open this folder and view contentsOnchocerciasis
Open this folder and view contentsSchistosomiasis
Open this folder and view contentsIntestinal, liver and lung flukes
View the documentSelected WHO publications of related interest
View the documentBack cover


Group: anthelminthic agent
Chewable tablet 200 mg, 400 mg

General information

A benzimidazole derivative that interferes with microtubule assembly and blocks glucose uptake by many intestinal and tissue nematodes and some cestodes.

It is poorly absorbed from the gastrointestinal tract and is rapidly and extensively metabolized in the liver. The absorbed fraction, which has a plasma half-life of some 8 hours, is largely eliminated in the urine as the sulfoxide.

Clinical information


Treatment of ascariasis, hookworm infections, strongyloidiasis, enterobiasis, trichuriasis, trichostrongyliasis and capillariasis.

Dosage and administration

Adults and children over 2 years: a single dose of 400 mg is sufficient to eliminate most cases of ascariasis, hookworm infection, enterobiasis, trichostrongyliasis, capillariasis and moderate T. trichiura infections.

Strongyloidiasis and heavy T. trichiura infections require a 3-day course of treatment.


• Known hypersensitivity.
• Early pregnancy.

Use in pregnancy

Albendazole has been shown to have teratogenic and embryotoxic potential in rats and rabbits. Although high priority should be accorded to the treatment of pregnant women, albendazole should not be administered during the first trimester.

Adverse reactions

Transient gastrointestinal discomfort and headache have occasionally been reported.


Emesis or gastric lavage may be of value if undertaken within a few hours of ingestion. Otherwise treatment is symptomatic and supportive. No specific antidote exists.


Tablets should be stored in well-closed containers.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018